Business Context and Reporting Period
This Form 8-K Current Report was filed by Perspective Therapeutics, Inc. (NYSE American: CATX) on August 16, 2024. The filing addresses a change in the Company's executive leadership structure regarding its principal financial and accounting officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Departure of Officer: Mark Austin ceased serving as Vice President of Finance, Corporate Controller, Corporate Secretary, co-principal financial officer, and principal accounting officer effective August 16, 2024.
- Appointment of Officer: Jonathan Hunt, previously the Chief Financial Officer and co-principal financial officer, assumed the roles of sole principal financial officer and principal accounting officer effective August 16, 2024.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No risks, contingencies, or unusual items were disclosed in this specific report. The Company confirmed there are no arrangements or understandings regarding Mr. Hunt's designation and no family relationships between Mr. Hunt and other directors or officers.
Investor Verification Checklist
- Verify the effective date of the leadership transition (August 16, 2024).
- Confirm Jonathan Hunt's biographical details in the Schedule 14A proxy statement filed on April 18, 2024.
- Review subsequent filings for any financial impact related to the departure of the Corporate Controller.